CD46 and antiphospholipid syndrome: Among the 11 surviving aHUS patients, reasons for cessation varied: two medical tourists returned to their home counties post-optimization, four (including two with CFH mutations) transitioned to other institutions, and five discontinued after sustained clinical improvement—three with pre-existing conditions (FSGS-related ESKD or antiphospholipid syndrome) and two additional patients (one with MCP genetic mutation) discontinued treatment after achieving sustained clinical improvement without relapse during follow-up period.